Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Prajnan Das

Showing results (201-210 of 324) with videos related to

Pageof 33
Sort By:
BMC Health Services Research|December 13, 2022
Using patient flow analysis with real-time patient tracking to optimize radiation oncology consultation visitsShane Mesko, Julius Weng, Prajnan Das, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|June 2, 2023
Salvage Locoregional Therapy Following Progression After Radiotherapy for Hepatocellular Carcinoma Is Associated with Improved OutcomesYuan-Mao Lin, Bryan M Fellman, Ryosuke Taiji, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2015
Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response AnalysisRanda Tao, Sunil Krishnan, Priya R Bhosale, et al.
Cancer|October 4, 2013
Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapyAtin Agarwal, George J Chang, Chung-Yuan Hu, et al.
Cancers|September 19, 2020
Trial Sponsorship and Time to Reporting for Phase 3 Randomized Cancer Clinical TrialsTimothy A Lin, Clifton David Fuller, Vivek Verma, et al.
International Journal of Radiation Oncology, Biology, Physics|October 24, 2006
Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysisPrajnan Das, Edward H Lin, Sumita Bhatia, et al.
Acta Oncologica (Stockholm, Sweden)|January 23, 2015
Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancerAwalpreet S Chadha, Esengul Kocak-Uzel, Prajnan Das, et al.
The Lancet. Oncology|October 31, 2021
Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trialChad Tang, Pavlos Msaouel, Kieko Hara, et al.
International Journal of Radiation Oncology, Biology, Physics|May 2, 2021
A Machine Learning Model Approach to Risk-Stratify Patients With Gastrointestinal Cancer for Hospitalization and Mortality OutcomesKaitlin M Christopherson, Prajnan Das, Christopher Berlind, et al.
Journal of Gastrointestinal Oncology|August 27, 2016
Continuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer: the MD Anderson experienceHumaid O Al-Shamsi, Yazan Fahmawi, Ibrahim Dahbour, et al.
Pageof 33

Showing results (201-210 of 324) with videos related to

Sort By:
Pageof 33
BMC Health Services Research|December 13, 2022
Using patient flow analysis with real-time patient tracking to optimize radiation oncology consultation visitsShane Mesko, Julius Weng, Prajnan Das, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|June 2, 2023
Salvage Locoregional Therapy Following Progression After Radiotherapy for Hepatocellular Carcinoma Is Associated with Improved OutcomesYuan-Mao Lin, Bryan M Fellman, Ryosuke Taiji, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2015
Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response AnalysisRanda Tao, Sunil Krishnan, Priya R Bhosale, et al.
Cancer|October 4, 2013
Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapyAtin Agarwal, George J Chang, Chung-Yuan Hu, et al.
Cancers|September 19, 2020
Trial Sponsorship and Time to Reporting for Phase 3 Randomized Cancer Clinical TrialsTimothy A Lin, Clifton David Fuller, Vivek Verma, et al.
International Journal of Radiation Oncology, Biology, Physics|October 24, 2006
Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysisPrajnan Das, Edward H Lin, Sumita Bhatia, et al.
Acta Oncologica (Stockholm, Sweden)|January 23, 2015
Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancerAwalpreet S Chadha, Esengul Kocak-Uzel, Prajnan Das, et al.
The Lancet. Oncology|October 31, 2021
Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trialChad Tang, Pavlos Msaouel, Kieko Hara, et al.
International Journal of Radiation Oncology, Biology, Physics|May 2, 2021
A Machine Learning Model Approach to Risk-Stratify Patients With Gastrointestinal Cancer for Hospitalization and Mortality OutcomesKaitlin M Christopherson, Prajnan Das, Christopher Berlind, et al.
Journal of Gastrointestinal Oncology|August 27, 2016
Continuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer: the MD Anderson experienceHumaid O Al-Shamsi, Yazan Fahmawi, Ibrahim Dahbour, et al.
Pageof 33